Tildrakizumab in Patients with Moderate-to-Severe Psoriasis: Post-Hoc Analyses on Efficacy, Time to Relapse, Long-Term Safety in Elderly Population and Predictability From The reSURFACE 1 and reSURFACE 2 Phase III Clinical Trials
Psoriasis is a chronic, relapsing inflammatory skin disease, characterised in most cases by sharply demarcated, erythematous, pruritic plaques covered…
